Dark

CBIO
Crescent Biopharma, Inc. Common Stock
stock NASDAQ

Market Open

Jul 28, 2026 3:15:49 PM EDT

16.39USD-3.190%(-0.54)128,178

16.25Bid 16.77Ask 0.52Spread

Pre-market

0.00USD-100.000%(-16.30)0

After-hours

Jul 27, 2026 4:00:30 PM EDT

16.93USD+0.059%(+0.01)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

08:10AM EST Catalyst Biosciences Receives Rare Pediatric Disease Designation For CB 4332 For The Treatment Of CFI Deficiency Benzinga

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID). GlobeNewswire Inc

Dec 21, 2021

12:32PM EST Catalyst Bio US Patent & Trademark Office Abstract For Co.'s 'Factor VII polypeptides that are modified and uses thereof' Benzinga

Dec 17, 2021

09:56AM EST UPDATE: Catalyst Bio FDA AccessData.gov Listing Dated Dec. 15, 2021 Benzinga

09:54AM EST Catalyst Bio FDA AccessData.gov Listing Shows Orphan Drug Designation For Co.'s ' Treatment of Bleeding Episodes in Patients with Hemophilia A or B, Including those with Inhibitors' Benzinga

Nov 22, 2021

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29-December 2, 2021. GlobeNewswire Inc

Nov 15, 2021

11:20AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 Benzinga

10:45AM EST Raymond James Downgrades Catalyst Biosciences to Market Perform Benzinga

Nov 12, 2021

11:23AM EST Looking Into Catalyst Biosciences's Return On Capital Employed Benzinga

07:00AM EST Company to discontinue MarzAA development; focus on developing its complement portfolio GlobeNewswire Inc

Oct 29, 2021

08:00AM EDT Catalyst Biosciences Announces CFI Variant Presentations at Two GlobeNewswire Inc

Oct 14, 2021

08:07AM EDT The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts Benzinga

Oct 13, 2021

04:06PM EDT Catalyst Biosciences Announces Clinton Musil Has Resigned From CFO; Seline Miller To Serve As Interim CFO Benzinga

04:05PM EDT Catalyst Biosciences Announces Chief Financial Officer Transition GlobeNewswire Inc

Oct 11, 2021

09:44AM EDT Catalyst Biosciences Sponsored Study Titled 'Screening Study to Identify Patients With Complement Factor I Deficiencies' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

07:23AM EDT Catalyst Biosciences' Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder Benzinga

Sep 28, 2021

04:02PM EDT FDA Grants Catalyst Biosciences Orphan Drug Designation For MarzAA For The Treatment Of Factor VII Deficiency Benzinga

04:01PM EDT FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA GlobeNewswire Inc

Sep 24, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will be broadcast as part of the Cantor Global Healthcare Conference at 10:00 am ET on Wednesday, September 29, 2021. GlobeNewswire Inc

Sep 15, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Wednesday, September 15, 2021 at 1:00 pm Eastern Time. GlobeNewswire Inc

Sep 9, 2021

08:13AM EDT Catalyst Biosciences Announces Oral, Poster Presentations At International Conference On Complement Therapeutics Benzinga

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented data at the International Conference on Complement Therapeutics (ICCT), being held September 8-13, 2021. GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Seasoned Biopharmaceutical Executive Adds Substantial Corporate Development Expertise GlobeNewswire Inc

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 6, 2021

12:08PM EDT Raymond James Maintains Outperform on Catalyst Biosciences, Lowers Price Target to $18 Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:38AM EDT Catalyst Biosciences Q2 EPS $(0.64) Up From $(0.96) YoY, Sales $1.13M Down From $1.66M YoY Benzinga

Jul 22, 2021

08:04AM EDT Catalyst Biosciences Announces First Patient Screened For CFI Deficiency In Its CB 4332 Screening And Natural History Of Disease Studies Benzinga

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the screening of the first patient in its CFI-deficiency study in the CB 4332 program, its wholly-owned, first-in-class, enhanced Complement Factor I (CFI), intended for prophylactic subcutaneous (SQ) administration in individualswith CFI deficiency. GlobeNewswire Inc

Jul 19, 2021

04:01PM EDT Catalyst Biosciences Presents Four Posters at the International Society for Thrombosis and Haemostasis 2021 Virtual Congress Benzinga

04:01PM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress, being held July 17-21, 2021. GlobeNewswire Inc

Jul 14, 2021

08:00AM EDT Catalyst Biosciences Announces Key Leadership Changes in its GlobeNewswire Inc

Jul 6, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced four poster presentations on marzaptacog alfa (activated) (MarzAA) and dalcinanonog alfa (DalcA) at the upcoming International Society on Thrombosis and Haemostatis (ISTH) Virtual Congress being held from July 17-21, 2021. GlobeNewswire Inc

Jul 1, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development day on its protease medicines platform focusing on the regulation of complement including CB 4332 on Monday, July 19, 2021 at 12:00 pm Eastern Time. GlobeNewswire Inc

Jun 28, 2021

08:45AM EDT Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA Benzinga

08:00AM EDT Catalyst Biosciences Receives FDA Fast Track Designation for GlobeNewswire Inc

Jun 10, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in fireside chats at the two investor conferences in June: Raymond James Human Health Innovation Conference and the JMP Securities Life Sciences Conference. GlobeNewswire Inc

May 18, 2021

08:17AM EDT Catalyst Biosciences Doses First Patient In Marzeptacog Alfa Phase 1/2 Study RTTNews

08:10AM EDT Catalyst Biosciences Announces First Patient Dosed In Marzeptacog Alfa (Activated) Phase 1/2 Study In Factor VII Deficiency, Glanzmann Thrombasthenia And Hemophilia A treated With Hemlibra Benzinga

08:00AM EDT Catalyst Biosciences Announces First Patient Dosed in Marzeptacog GlobeNewswire Inc

May 13, 2021

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Truist Securities Life Sciences Summit at 1:00 pm ET on Monday, May 17, 2021. GlobeNewswire Inc

May 6, 2021

08:56AM EDT Catalyst Biosciences Q1 EPS $(0.79) Down From $(0.28) YoY, Sales $1.47M Down From $16.37M YoY Benzinga

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and provided a corporate update. GlobeNewswire Inc

May 5, 2021

08:09AM EDT Catalyst Biosciences Says First Patient Dosed In Pivotal Phase 3 Registration Study Of SQ MarzAA In Individuals With Hemophilia A Or B With Inhibitors Benzinga

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3 registration trial (MAA-304 - Crimson 1) of Marzeptacog alfa (activated) or MarzAA, the Company's subcutaneously (SQ) administered next-generation engineered recombinant coagulation Factor VIIa (rFVIIa). GlobeNewswire Inc

Apr 29, 2021

07:22AM EDT Raymond James Maintains Outperform on Catalyst Biosciences, Raises Price Target to $19 Benzinga

Apr 19, 2021

08:13AM EDT Catalyst Biosciences Highlights Publication Of CB 2679d Preclinical FIX Gene Therapy Data In Blood Journal of the American Society of Hematology Benzinga

08:00AM EDT Catalyst Biosciences Announces Publication of CB 2679d Preclinical GlobeNewswire Inc

Apr 12, 2021

08:01AM EDT Catalyst Biosciences Says Expands Protease Medicines Patent Portfolio Of Complement Factor 3 Degraders Benzinga

08:00AM EDT Catalyst Biosciences Expands its Protease Medicines Patent GlobeNewswire Inc

Apr 7, 2021

04:05PM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 pm ET on Thursday, April 15, 2021. GlobeNewswire Inc

Mar 23, 2021

11:24AM EDT Catalyst Biosciences shares were trading higher the company announced that it was awarded a U.S. Patent on 'Nucleic acid encoding modified membrane-type serine protease 1 (MTSP-1) polypeptides and methods of use'. Benzinga

Mar 4, 2021

08:11AM EST Catalyst Biosciences Q4 EPS $(0.86) Up From $(1.23) YoY Benzinga

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year ending December 31, 2020 and provided a corporate update. GlobeNewswire Inc

Feb 18, 2021

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its executive management team will participate in a fireside chat at the Raymond James 42nd Annual Institutional Investors Conference at 2:10 pm ET on Wednesday, March 3, 2021. GlobeNewswire Inc

Feb 11, 2021

04:01PM EST Catalyst Biosciences Announces Partial Exercise and Closing of GlobeNewswire Inc

Feb 10, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 Benzinga

06:46AM EST Piper Sandler Initiates Coverage On Catalyst Biosciences with Overweight Rating, Announces Price Target of $15 Benzinga

Feb 4, 2021

05:21AM EST Raymond James Maintains Outperform on Catalyst Biosciences, Lowers Price Target to $18 Benzinga

Feb 3, 2021

08:03AM EST Catalyst Biosciences Reports Presentation Of Pre-Clinical Subcutaneously Administered Engeineered Activated Coagulation Factor VII For Treatment Of Episodic Bleeding Benzinga

08:00AM EST Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds GlobeNewswire Inc

Jan 29, 2021

04:01PM EST Catalyst Biosciences Announces Closing of Public Offering of GlobeNewswire Inc

Jan 27, 2021

08:12AM EST Catalyst Biosciences Prices Public Offering Of 8.7 Mln Shares At $5.75/Shr RTTNews

08:05AM EST Catalyst Biosciences Prices 8.7M Share Offering AT $5.75/Share Benzinga

08:00AM EST Catalyst Biosciences Announces Pricing of Public Offering of GlobeNewswire Inc

Jan 26, 2021

04:04PM EST Catalyst Biosciences Reports Common Stock Offering, No Size Disclosed Benzinga

04:04PM EST Catalyst Biosciences Announces Proposed Public Offering of Common GlobeNewswire Inc

Jan 20, 2021

08:01AM EST Catalyst Biosciences Announces Poster Presentations At EAHAD 2021 Virtual Congress Benzinga

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress being held on February 3 - 5, 2021. GlobeNewswire Inc

Jan 15, 2021

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hosted by LifeSci Capital on Tuesday, January 19, 2021 at 1:00 pm Eastern Time. GlobeNewswire Inc

Dec 7, 2020

08:24AM EST Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design At 62nd Annual American Society Of Hematology Conference Benzinga

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held virtually December 5-8, 2020, highlighting its Phase 3 Study, Crimson 1. The study will evaluate Marzeptacog alfa (activated) or MarzAA, the Companys subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa). GlobeNewswire Inc

Dec 3, 2020

04:02PM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Companys systemic complement regulator programs on Monday, December 14, 2020 at 12:00 pm Eastern Time. GlobeNewswire Inc

Dec 2, 2020

08:00AM EST Catalyst Biosciences Receives FDA Fast Track Designation for GlobeNewswire Inc

Nov 24, 2020

04:02PM EST Catalyst Biosciences To Present At 32nd Annual Piper Sandler Virtual Healthcare Conference Dec. 1-3 Benzinga

04:01PM EST Catalyst Biosciences to Present at 32nd Annual Piper Sandler GlobeNewswire Inc

Nov 5, 2020

09:09AM EST Catalyst Biosciences Announces Poster Presentation At 62nd Annual American Society Of Hematology Conference Dec. 6 Benzinga

09:01AM EST Catalyst Biosciences Announces Poster Presentation At 62nd Annual American Society Of Hematology Conference Benzinga

08:10AM EST Catalyst Biosciences Q3 EPS $(0.73) Up From $(1.06) YoY, Sales $893.00M Benzinga

Nov 3, 2020

08:00AM EST Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced thatNassim Usman, Ph.D., president and chief executive officer, and Clinton Musil, chief financial officer, ofCatalyst Biosciences will present at the Stifel 2020 Virtual Healthcare Conference taking place on November 16-18, 2020. Details for the company presentation are as follows: GlobeNewswire Inc

Oct 14, 2020

08:04AM EDT Catalyst Biosciences Receives US Patent For Its Anti-Complement Factor 3 Portfolio Of Engineered Proteases Benzinga

08:00AM EDT Catalyst Biosciences Receives US Patent for its Anti-Complement GlobeNewswire Inc

Sep 25, 2020

08:00AM EDT Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced thatGrant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: The evolution of complement targeted therapies, taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time. GlobeNewswire Inc

Sep 10, 2020

08:00AM EDT Catalyst Biosciences to Participate in Two Upcoming Investor GlobeNewswire Inc

Aug 6, 2020

09:29AM EDT Catalyst Biosciences Earlier Reported Q2 EPS $(0.96) Up From $(1.15) YoY Benzinga

Jul 15, 2020

01:40PM EDT Chembio Shares Spike; Co. Wins $628K Contract From Health And Human Services Benzinga

Jul 13, 2020

08:09AM EDT Catalyst Biosciences Presents Data At The International Society For Thrombosis And Haemostasis Virtual Congress Benzinga

08:00AM EDT Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels GlobeNewswire Inc